本帖最后由 老马 于 2013-3-13 13:43 编辑 ! E/ m6 o& p1 ?7 i+ J$ R C
( L; u! p6 V1 {- o2 H- a: i; H8 u
健择(吉西他滨)+顺铂+阿瓦斯汀
R7 @0 e, J& r5 B: \ Gemzar +Cisplatin + Avastin. s2 ^6 v7 f4 k
http://annonc.oxfordjournals.org/content/21/9/1804.full
" _5 n! E4 v+ FOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* B+ A6 l$ J X" f5 fPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
r! u9 q4 Q( l# r+ ~4 }Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 `8 l$ g: k+ k9 E- D6 E
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 231)
3 m. u7 K& @% u9 S! D" ^
华为网盘附件:) X4 p- X" O' s* _ s, w9 G6 `
【华为网盘】ava.JPG, h- j+ c; ]% ?
|